Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression (BLAD)

torstai 16. heinäkuuta 2026 päivittänyt: Prof. Massimo Filippi, IRCCS San Raffaele

The Diagnostic and Prognostic Role of Plasma Biomarkers in Alzheimer's Disease

BLAD is a prospective, monocentric, observational epidemiological study with an additional procedure (annual blood draw) evaluating the diagnostic and prognostic performance of plasma biomarkers for Alzheimer's disease (AD) in a large cohort of patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy.

2000 patients will be enrolled and followed annually for 5 years. A validation sub-study (150 patients) will compare plasma biomarkers against CSF biomarkers as the gold standard.

The study aims to establish plasma biomarkers as a less invasive and more cost-effective alternative to CSF analysis and amyloid-PET for the diagnosis and prognosis of AD.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

In light of the possible advent of disease-modifying drugs for Alzheimer's disease (AD), reliable biomarkers have been developed in recent years to define the presence of AD pathology at the brain level. The current biological gold standards are cerebrospinal fluid (CSF) biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) and amyloid-PET. Both methods have excellent diagnostic properties but are costly and invasive, limiting their use outside of highly specialized centers.

Plasma biomarkers (plasma-Abeta40, plasma-Abeta42, plasma-pTau-181, plasma-NfL, plasma-ApoE, plasma-ApoE4, plasma-GFAP, plasma-sTREM2, and other plasma neurodegeneration biomarkers) represent a potentially less invasive and more economically accessible alternative. Recent studies have shown that plasma biomarkers can differentiate AD from other neurodegenerative disorders with accuracy comparable to CSF and PET, detect AD pathology in MCI patients, and predict future development of AD dementia in patients with SCD or MCI. However, more research is needed before their widespread use in clinical practice.

The BLAD study is designed as a monocentric, prospective, observational epidemiological study with an additional procedure (annual blood draw for 5 years) and a diagnostic accuracy sub-study (not device-based).

Patients will be recruited among those attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital during routine clinical practice. All enrolled patients will undergo annual blood sampling for 5 years in addition to standard clinical assessments.

A sub-population of 150 patients who undergo lumbar puncture as part of their routine diagnostic workup will enter the validation sub-study. Only those whose CSF biomarkers confirm a biological diagnosis of Alzheimer's disease will continue follow-up; others will exit the sub-study.

The equipment for plasma biomarker measurement (CE-marked medical device) and laboratory kits will be provided on free loan by Fujirebio. No clinical or laboratory data will be shared with Fujirebio.

Statistical analyses will include: log-rank test to compare time to AD development between groups above and below the biomarker threshold; linear stepwise regression models, linear mixed-effects models, and multivariable Cox models to assess the prognostic value of plasma biomarkers; longitudinal generalized linear models for repeated measures or Wilcoxon test to assess biomarker dynamics over time. For the validation sub-study, ROC curve analysis will be performed to assess accuracy, sensitivity, and specificity of plasma biomarkers against CSF gold standard.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

2000

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Giuseppe Magnani, MD

Opiskelupaikat

  • Italia
    • Milano
      • Milan, Milano, Italia, 20132
        • Rekrytointi
        • IRCCS Ospedale San Raffaele - Cognitive Disorders and Dementia Center (CDCD)
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:
          • Giuseppe Magnani, MD
        • Päätutkija:
          • Massimo Filippi, Prof, MD
        • Alatutkija:
          • Federica Agosta, MD
        • Alatutkija:
          • Giuseppe Magnani, MD
        • Alatutkija:
          • Giordano Cecchetti, MD
        • Alatutkija:
          • Francesca Caso, MD
        • Alatutkija:
          • Roberto Santangelo, MD
        • Alatutkija:
          • Gioele Spinelli, MD
        • Alatutkija:
          • Giulia Rugarli, MD
        • Alatutkija:
          • Federico Coraglia, MD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital, Milan, Italy, presenting with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature.

Kuvaus

Inclusion Criteria (main study and sub-study):

  1. Age greater than or equal to 40 years (patients of childbearing age are admitted).
  2. Subjective or objective cognitive complaints, progressive in nature and of suspected neurodegenerative origin.

  3. Mini-Mental State Examination (MMSE) score greater than or equal to 18.

    Additional inclusion criterion for the validation sub-study:

  4. Availability of CSF biomarkers for Alzheimer's disease within 6 months of the blood draw.

Exclusion Criteria (main study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy or breastfeeding.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who require a legal guardian or tutor.

Exclusion Criteria (validation sub-study):

  1. Secondary forms of cognitive impairment based on medical history, neurological examination, and neuroimaging findings.
  2. Pregnancy.
  3. Rapidly progressive cognitive decline occurring over weeks or months, typically indicative of prion disease, neoplasia, or metabolic disorders.
  4. Subjects who are unable to give informed consent and require a legal guardian or tutor.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Main Study Cohort
2000 adult patients attending the Cognitive Disorders and Dementia Center (CDCD) at IRCCS San Raffaele Hospital with subjective or objective cognitive complaints of progressive and suspected neurodegenerative nature. All patients undergo annual blood sampling for 5 years in addition to standard clinical follow-up.
Menettely: Annual blood draw for plasma biomarker measurement
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.
Validation Sub-study Cohort
150 patients from the main cohort who undergo lumbar puncture as part of their routine diagnostic workup and have CSF biomarkers for Alzheimer's disease available within 6 months of blood draw. Only those with CSF biomarkers confirming a biological diagnosis of Alzheimer's disease continue longitudinal follow-up in the sub-study.
Menettely: Annual blood draw for plasma biomarker measurement
A blood sample is collected once per year for 5 years (additional procedure beyond standard clinical care) for measurement of plasma biomarkers including: Abeta40, Abeta42, Abeta42/Abeta40 ratio, pTau-181, NfL, ApoE, ApoE4, GFAP, sTREM2, and other plasma neurodegeneration biomarkers. Blood draw is a routine clinical procedure with no specific contraindications. The only possible side effect is local hematoma at the puncture site. Plasma biomarker measurement is performed using a CE-marked medical device (Fujirebio, provided on free loan). Results do not modify the patient's standard diagnostic and therapeutic pathway.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Time to progression to all-cause dementia in MCI patients (primary prognostic endpoint)
Aikaikkuna: Annually from baseline up to 5 years
Time to clinical progression to all-cause dementia in patients with Mild Cognitive Impairment (MCI) at baseline, assessed using multivariable Cox proportional hazards models. For each plasma biomarker, patients are divided into two groups (above/below the median) and compared using the log-rank test (cause-specific hazard). The study has greater than 95% power to detect a Hazard Ratio of 2 and approximately 75-80% power for HR of 1.5.
Annually from baseline up to 5 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in MMSE score over time
Aikaikkuna: Annually from baseline up to 5 years
Change over time in Mini-Mental State Examination (MMSE) score as a measure of cognitive progression. A decrease of 5 or more points is considered clinically significant progression of cognitive impairment due to AD.
Annually from baseline up to 5 years
Conversion from MCI to Alzheimer's disease dementia
Aikaikkuna: Annually from baseline up to 5 years
Rate of clinical conversion from Mild Cognitive Impairment (MCI) to Alzheimer's disease dementia over the 5-year follow-up period, assessed at each annual visit.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42/Abeta40 ratio
Aikaikkuna: Annually from baseline up to 5 years
Change over time in the plasma Abeta42/Abeta40 ratio, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma pTau-181 levels
Aikaikkuna: Annually from baseline up to 5 years
Change over time in plasma phosphorylated tau 181 (pTau-181) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma NfL levels
Aikaikkuna: Annually from baseline up to 5 years
Change over time in plasma neurofilament light chain (NfL) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma GFAP levels
Aikaikkuna: Annually from baseline up to 5 years
Change over time in plasma Glial Fibrillary Acidic Protein (GFAP) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma sTREM2 levels
Aikaikkuna: Annually from baseline up to 5 years
Change over time in plasma soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta40 levels
Aikaikkuna: Annually from baseline up to 5 years
Change over time in plasma beta-amyloid 40 (Abeta40) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years
Longitudinal change in plasma Abeta42 levels
Aikaikkuna: Annually from baseline up to 5 years
Change over time in plasma beta-amyloid 42 (Abeta42) levels, assessed using longitudinal generalized linear models for repeated measures or Wilcoxon test.
Annually from baseline up to 5 years

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Diagnostic accuracy of plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma Abeta42/Abeta40 ratio in diagnosing Alzheimer's disease, using CSF biomarkers (CSF-Abeta40, CSF-Abeta42, CSF-pTau, CSF-NfL) as the gold standard. Patients are classified as AD or non-AD based on CSF results. An AUC of at least 0.80 is expected, with greater than 95% power to reject H0: AUC=0.50 at alpha=0.05.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma pTau-181 vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma pTau-181 in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma NfL vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma NfL in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Diagnostic accuracy of plasma GFAP vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Area under the ROC curve (AUC), sensitivity, and specificity of plasma GFAP in diagnosing Alzheimer's disease, using CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta40 vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta40 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42 vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta42 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma Abeta42/Abeta40 ratio vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for Abeta42/Abeta40 ratio biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma pTau-181 vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for pTau-181 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma NfL vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for NfL biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma GFAP vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for GFAP biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma sTREM2 vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for sTREM2 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for ApoE biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)
Optimal diagnostic cut-off values for plasma ApoE4 vs CSF gold standard (sub-study)
Aikaikkuna: Baseline (at time of lumbar puncture, within 6 months of blood draw)
Determination of the optimal diagnostic cut-off values for ApoE4 biomarker using ROC curve analysis against CSF biomarkers as the gold standard.
Baseline (at time of lumbar puncture, within 6 months of blood draw)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

IRCCS San Raffaele

Tutkijat

  • Päätutkija: Massimo Filippi, Prof, MD, IRCCS San Raffaele

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 12. syyskuuta 2023

Ensisijainen valmistuminen (Arvioitu)

Tiistai 1. kesäkuuta 2032

Opintojen valmistuminen (Arvioitu)

Tiistai 1. kesäkuuta 2032

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 16. heinäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 16. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 21. heinäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 21. heinäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 16. heinäkuuta 2026

Viimeksi vahvistettu

Keskiviikko 1. heinäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • BLAD

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Kliiniset tutkimukset Kognitiivinen rajoite

Hae vastaavia kokeiluja

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

CROs by country

CROs in Brazil

Ehdot

Harvinaiset sairaudet

Huumeiden interventiot

Ravintolisät

Sponsori / yhteistyökumppanit

Sijainnit

Tilaa